Topographic Association between Tau Pathology and Atrophy Correlated with

Key Symptoms in Progressive Supranuclear Palsy

Yuko Kataoka, MD, PhD,[1] Ryoji Goto, MD,[1] Yoshikazu Chishiki, MD,[1] Kenta Osawa,

MD,[1] Asaka Oyama, MSc,[1] Hideki Matsumoto, DDS, PhD,[1,3] Masanori Ichihashi,

MD,[1] Sho Moriguchi, MD, PhD[1], Yuki Momota, PhD,[1] Tetsuji Kamada, PhD[1], Chie

Seki, PhD,[1] Kiwamu Matsuoka, MD, PhD,[1] Kosei Hirata, MD, PhD,[1] Shin Kurose,

MD,[1] Masaki Oya, MD,[1] Naomi Kokubo, PhD,[1] Hitoshi Shinotoh, MD, PhD,[1]

Hitoshi Shimada, MD, PhD,[1,4] Kazunori Kawamura, PhD,[2] Ming-Rong Zhang, PhD,[2]

Takahiko Tokuda, MD, PhD,[1,5] Keisuke Takahata, MD, PhD,[1] Kenji Tagai, MD, PhD,[1]

Makoto Higuchi, MD, PhD,[1,5] Hironobu Endo, MD, PhD[1]

[1] Advanced Neuroimaging Center, Institute for Quantum Medical Science, National

Institutes for Quantum Science and Technology (QST), Chiba, Japan

[2] Department of Advanced Nuclear Medicine Sciences, Institute for Quantum

Medical Science, QST, Chiba, Japan

[3] Department of Oral and Maxillofacial Radiology, Tokyo Dental College, Tokyo,

Japan

[4] Department of Functional Neurology & Neurosurgery, Center for Integrated Human

Brain Science, Brain Research Institute, Niigata University, Niigata, Japan

[5] Department of Neuroetiology and Diagnostic Science, Osaka Metropolitan

University Graduate School of Medicine, Osaka, Japan

Correspondence to Hironobu Endo, MD, PhD

Advanced Neuroimaging Center, Institute for Quantum Medical Science, National

Institutes for Quantum Science and Technology, Chiba 263-8555, Japan

E-mail: endo.hironobu@qst.go.jp

TEL: +81-43-206-3249

Number of words in titles: 131/140

Short titles: Topographic Association of Tau Pathology and Atrophy with Key

Symptoms in PSP

Number of words in short titles: 77/100

Number of words in abstract: 341/350

Number of words in main text: 4409/4500

Number of figures: 3

Number of tables: 2

Funding: Disclosures and author roles are found in the online version of this article.

Abstract

[Background and Objectives] Progressive supranuclear palsy (PSP) is a four-repeat

tauopathy characterized by subcortical atrophy and distinctive motor impairments.

Although tau pathology is presumed to drive neuronal loss, the spatial relationships

between tau deposition, regional atrophy, and domain-specific symptoms remain

incompletely understood. This study aimed to compare the distributions of tau

pathology and atrophy related to key motor symptom domains in PSP, and to clarify

their distinct contributions to clinical manifestations.

[Methods] We conducted a prospective, single-center observational study. PSP cases

underwent neurological assessments, including the PSP Rating Scale, which covers six

domains. Tau positron emission tomography (PET) with florzolotau (18F) and T1-

weighted magnetic resonance imaging were acquired from these patients and healthy

controls to assess correlations of domain scores with tau accumulation and local brain

volumes. Path analysis was performed to explore spatiotemporal relationships between

tau deposits and volume loss leading to individual domains.

[Results] Fifty-eight PSP patients and 52 healthy controls were included. Subcortical tau

accumulation and atrophy showed significant spatial overlap and were closely

associated with motor deficits. The "ocular motor" domain scores correlated with tau in

the midbrain tegmentum and globus pallidus, and the "gait and midline" domain scores

correlated with tau in the globus pallidus, thalamus, and subthalamic nucleus. In

contrast, tau deposits and volume reductions in separate neocortical regions were linked

to the manifestations. Indeed, the "limb motor" domain scores correlated with tau in the

primary motor and somatosensory cortices, and atrophy in the angular, supramarginal,

and temporal cortices. Path analysis suggested that tau in subcortical structures may

elicit local neuronal loss, impairing the "ocular motor" and "gait and midline" domains,

while tau in the neocortex likely affects the "limb motor" domain through local and

subsequent network-mediated neurotoxicity.

[Discussion] High-contrast tau imaging clarifies the neuropathological basis of key

symptoms in living PSP patients and highlights distinct tau-induced neurotoxic effects

in subcortical versus neocortical regions. These findings indicate that PSP key

symptoms arise from anatomically and mechanistically distinct tau-neurodegeneration

pathways, underscoring the significance of PET-detectable regional tau depositions as

surrogates for and predictors of clinical manifestations.

Introduction

Progressive supranuclear palsy (PSP) is an idiopathic neurodegenerative

disorder lacking effective treatments. Clinically, it manifests with motor impairments

resembling Parkinson's disease, alongside distinctive features like ocular motor

dysfunction and postural instability. Neuropathologically, PSP is characterized by

neuronal and glial inclusions composed of four-repeat tau isoforms, including globose

tangles, coiled bodies, and tufted astrocytes. These tau aggregates predominantly affect

subcortical structures such as the thalamus, subthalamic nucleus, and brainstem,

although neocortical regions, particularly in the frontal lobe, are also frequently

involved.[1-4] Accordingly, PSP is classified within frontotemporal lobar degeneration

with tau pathology (FTLD-Tau).[5]

A hallmark of PSP in morphometric neuroimaging is midbrain atrophy,

commonly recognized as the hummingbird sign[6], correlating with neurological deficits

assessed by the PSP Rating Scale.[7] Tau deposits are thought to contribute to neuronal

loss, particularly in the brainstem. However, the extent to which tau accumulation leads

to regional volume loss through direct or network-mediated effects remains unclear.

Investigating these processes in vivo could provide crucial insights into the pathological

basis of symptomatic manifestations. While animal models expressing four-repeat tau

isoforms exhibit neuronal loss,[8] their ability to replicate PSP-specific neurotoxic

mechanisms remains uncertain. Moreover, while PSP-derived tau fibril inoculation in

rodents induces neuronal and glial tau pathologies,[9] prominent neuronal loss leading to

measurable atrophy has not been observed.

Given these discrepancies, it is crucial to establish links among tau aggregation,

neuronal loss, and functional decline using human data. Although postmortem studies

have delineated tau inclusions in PSP brains,[4,10] they do not correlate with antemortem

symptoms, underscoring the value of in vivo assessments to explore spatial

relationships between tau pathology, brain atrophy, and symptom severity.

Recently, we developed a tau positron emission tomography (PET) radioligand,

florzolotau (18F), which exhibits high contrast for various tau pathologies, including

those in PSP.[11] Florzolotau (18F) enabled in vivo visualization of tau deposits in the

thalamus, subthalamic nucleus, basal ganglia, midbrain, and motor cortices in PSP

patients,[11,12] findings align with neuropathological observations. Two independent

studies have demonstrated a strong correlation between florzolotau (18F) retention in

the subthalamic nucleus and/or midbrain and total PSP Rating Scale scores.[11,13]

Extending these findings, a recent study applied a subtype/stage inference

algorithm to florzolotau (18F) PET data and identified distinct progression patterns of

tau deposition in PSP, underscoring the potential of machine learning to capture disease

heterogeneity and temporal dynamics.[14] Despite these results, large-scale PET

investigations are warranted to elucidate the evolution of tau pathology and its impact

on key clinical domains, such as impaired eye movements and gait abnormalities.

Previous studies using flortaucipir (18F) examined tau pathology and brain

atrophy in PSP patients across various symptomatic subtypes,[15] but did not correlate

imaging with motor deficits. Furthermore, an imaging-pathology correlation analysis

suggested flortaucipir (18F) has limited sensitivity for four-repeat tau aggregates in

FTLD,[16] questioning its utility for staging PSP.[17] Several studies have evaluated the

visual assessment of 4□repeat tauopathies using this tracer, [18,19] and others have

demonstrated that [¹□F]PI-2620 retention in the globus pallidus correlates with disease

severity in PSP.[20] Compared with [¹□F]PI-2620, flortaucipir (18F) enables visualization

of tau deposition across a broader range of brain areas,[21] including the midbrain, pons, subthalamic nucleus, thalamus, and precentral cortex, consistent with the distribution of tau inclusions confirmed by postmortem assays. Notably, our recent neuropathological investigation of a PSP case who had undergone PET scans has further supported the utility of this radiotracer for quantitative assessment of 4-repeat tau inclusions across diverse anatomical structures.[22]

Leveraging the ability of florzolotau (18F) to capture tau aggregates in region-specific patterns, the present study aimed to identify the spatial distributions of tau pathology and volumetric loss that underlie key symptomatic domains in a PSP cohort. By examining the concordance and discordance between florzolotau (18F) PET and volumetric MRI, we seek to determine whether four-repeat tau accumulation induces neurotoxicity locally or via network-mediated pathways. Additionally, path analysis of cross-sectional data was implemented to estimate the chronological progression of tau-induced neuronal damage associated with symptom categories.

Methods

Participants

A clinical study was conducted at the National Institutes for Quantum Science and Technology, Japan, between January 2018 and May 2023. It involved 52 consecutive healthy controls (HCs) and 58 consecutive patients with progressive supranuclear palsy (PSP). The diagnosis of PSP was based on the International Parkinson and Movement Disorder Society clinical criteria,[23] and only patients who fulfilled the criteria for *probable PSP* or a more definitive category were included.

HCs were defined as individuals aged 35 years or older with no history of

neurological impairment, a Mini-Mental State Examination score of ≥28, and a

Geriatric Depression Scale score of ≤5 or no history of depression.

PSP severity was assessed using the PSP Rating Scale,[24] which includes the

following domains: history, mentation, bulbar function, ocular motor function, gait and

midline stability, and limb motor function. The PSP Rating Scale was administered and

scored by board-certified, experienced neurologists. Frontal lobe function was further

assessed using the Frontal Assessment Battery (FAB).[25]

All participants were recruited from a dedicated volunteer registry. Aβ-positive

cases were excluded based on visual assessment of [^{11}C]Pittsburgh Compound-B

([^{11}C]PiB) PET scans, independently reviewed by at least three experienced PET

specialists.[26] Details regarding case exclusions are provided in the supplementary figure

(Figure S1) and the trial patient flow diagram.

MRI Studies

The participants underwent 3-T MAGNETOM Verio (Siemens Healthcare) and

3-T MAGNETOM Prisma (Siemens Healthcare) scanning. T1-weighted gradient-echo

sequence imaging (sagittal orientation; 1-mm-thick sections; echo time [TE], 1.95 ms;

repetition time [TR], 2,300 ms; flip angle, 9.0°; inversion time [TI], 900 ms; field of

view [FOV], 250 mm; matrix dimension, $512 \times 512 \times 176$) was executed for

coregistration of PET images into an individual anatomical space and their

segmentation for region-based quantification.

PET Studies

Amyloid pathology was assessed using [^{11}C]PiB PET, with a Biograph mCT

Flow system (Siemens Healthcare; matrix dimension, $200 \times 200 \times 109$; voxel size [mm],

$2 \times 2 \times 2$) or a Discovery MI scanner (GE Healthcare; matrix size: $128 \times 128 \times 89$;

voxel size: $2 \times 2 \times 2.8$ mm³ for [¹¹C]PiB scans). [¹¹C]PiB images were obtained over a

50–70-minute period (typically 4×5-minute frames) following an intravenous bolus

injection (514.8 ± 82.6 MBq).

Tau accumulation was assessed using PET with the radioligand florzolotau

(18F) on a Biograph mCT Flow system (Siemens Healthcare; matrix dimension,

$200 \times 200 \times 109$; voxel size [mm], $2 \times 2 \times 2$). List-mode event data were reconstructed

into PET images using a filtered back-projection algorithm with a Hanning filter (6.0

mm full width at half maximum). Each participant underwent a 20-minute PET scan

(frames: 4×5 or 2×10 min) 90 min after the intravenous injection of florzolotau (18F)

(193.4 ± 48.6 MBq).

[¹¹C]PiB and florzolotau (18F) PET scans were completed within a 3-month

interval. The PET scan protocol in detail was provided elsewhere.[11,27,28]

Data Analysis

Voxel-based analysis was conducted using tau PET images transformed into the

standard brain space via DARTEL (Details are provided in the eMethods section of the

supplementary material.). Tau accumulation and brain atrophy in PSP versus HC

subjects were analyzed by identifying regions of voxels with a family-wise error

correction at peak-level (FWEp) of $P < 0.05$ and the voxel number exceeding assigned

values. The association of tau accumulation and brain volume with neurological

symptoms was evaluated to pick up voxel clusters with predefined height and extent

thresholds. The association of tau depositions and brain volume with neurological

symptoms was assessed using a threshold of FWE correction at cluster-level (FWEc) P

< 0.05.

Based on voxel-wise analyses, areas of tau accumulation and volume loss that

correlated with each neurological symptom were binarized as ROIs. Using these ROIs,

florzolotau (18F) SUVRs and brain volumes were calculated for each PSP case. Path

analysis was used to estimate the relationships among tau accumulations (florzolotau

(18F) SUVRs), structural atrophy, and scores of PSP Rating Scale subdomains,

assuming a specified causal direction. Details of these analyses are provided in the

supplementary flow map (Figure S2). The assessments were performed using RStudio

(version 2024.12.1+563, RStudio, PBC) and the R package lavaan[29] (version 0.6–16).

Path models were estimated using the robust maximum likelihood estimator

(MLR); PSP Rating Scale subdomain scores were treated as ordinal variables due to

their inherently ranked distributions. MLR was applied to provide estimates robust to

non-normality. We defined tau deposition as an independent variable, atrophy as a

mediator, and symptomatic domain as a dependent variable, and investigated direct and

indirect effects. The model fit was evaluated using the normed fit index, comparative fit

index, and root mean square error approximation in all patients with PSP. Akaike's

information criterion was used to determine a better model. In addition, participants

were divided into three groups according to the disease duration, consisting of early (1

year), intermediate (2 years), and advanced (≥3 years) chronological stages. Path

analysis was then applied to individual stages to assess time-course changes in the

contribution of the independent variable and mediator to the outcome measure.

Statistical Analysis

Independent sample t- and χ^2 tests were conducted to compare baseline

demographics and clinical characteristics. All these statistical tests were two-tailed, with

$P < 0.05$ indicating statistical significance. Values were all reported as means with

standard deviations. Statistical analyses for demographics were performed using EZR

version 1.68 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a

graphical user interface for R version 4.3.1 (The R Foundation for Statistical Computing,

Vienna, Austria),[30] and Prism 9 for Windows 64-bit, version 9.5.1 (733) (GraphPad

Software, Boston, USA).

Data Sharing

Requests for data supporting our findings should be directed to the

corresponding author, Hironobu Endo (endo.hironobu@qst.go.jp).

Standard Protocol Approvals, Registrations, and Patient Consents

The study protocol was approved by the Ethics Committee of the National

Institutes for Quantum Science and Technology. Written informed consent was obtained

from all participants. The study was registered in the UMIN Clinical Trials Registry

(registration numbers 000026385, 000029608, and 000030248).

Data Availability

The data supporting our study findings are available from the corresponding

author upon reasonable request.

Results

Patient Backgrounds

The demographic profiles of the PSP patients and HCs are provided in Table 1.

Exhaustive Voxel-based Assessments

Comparisons between the PSP and HC groups

The retention of florzolotau (18F) was enhanced in the subcortical structures,

such as the midbrain, basal ganglia, and frontal regions in PSP cases relative to HCs

(red and yellow in Figure 1), in line with the distribution of tau pathologies in this

illness. These patients also presented reduced volumes of characteristic brain areas,

including the midbrain, basal ganglia, thalamus, and cerebellar hemispheres, compared

with HCs (green and yellow in Figure 1). There were notable spatial overlaps between

tau depositions and atrophy in the midbrain and basal ganglia (yellow in Figure 1).

Topology of tau accumulation and volume loss associated with neurological symptoms

(A) Total PSP Rating Scale scores

Intensified florzolotau (18F) signals and concomitant volume declines in

subcortical locations, including the midbrain, subthalamic nucleus, and globus pallidus,

were correlated with higher total PSP Rating Scale scores (upper left panels in Figure 2).

In contrast, tau accumulation in neocortical regions such as the primary and

supplementary motor cortices also correlated with symptom severity, despite the

absence of marked local atrophy.

(B) Ocular motor symptom domain

Tau accumulations and reduced volumes in subcortical structures, including the

midbrain tegmentum and globus pallidus, were correlated with elevated PSP Rating

Scale subscores in the ocular motor domain (upper right panels in Figure 2). The voxels

highlighted in PET and MRI assays presented remarkable spatial overlaps.

(C) Gait and midline symptom domain

Tau depositions and volume reductions in subcortical structures, including the

subthalamic nucleus and surrounding thalamic regions, alongside the globus pallidus,

showed correlations with increases of PSP Rating Scale subscores in the gait and

midline domain (lower left panels in Figure 2). The voxels highlighted in tau PET and

MRI assays displayed notable overlaps in these locations. In addition, we observed

associations of tau accumulations in the occipital cortex and volume loss in the occipital

cortex and precuneus with this symptomatic domain. The neocortical voxels highlighted

by tau PET and MRI showed little spatial overlap.

(D) Limb motor symptom domain

Unlike the symptom domains (A)-(C), only limited spatial overlap was

observed between regions in which tau deposition and volume loss were associated with

limb motor impairment (lower right panels in Figure 2). Tau accumulation, as related to

the PSP Rating Scale limb motor subscores, mainly involved the primary motor and

somatosensory cortices. In contrast, symptom-related atrophy was predominantly

localized to the angular and supramarginal gyri and temporal lobes, including both gray

and white matter. Although minor overlap near boundaries was present, the principal

foci of tau lesions and atrophy were spatially dissociated.

Three-dimensional renderings of all tau-loaded and atrophic regions associated

with domains (A)-(D) are shown in Figs. S3 and S4.

(E) Other categories

We found no brain areas exhibiting correlations of tau accumulations and

atrophy with PSP Rating Scale subscores in history, mentation, and bulbar categories.

Path Analysis Exploration of Causal Directions

Areas of tau accumulation and volume loss correlated with each neurological

symptom were binarized as ROIs. Using these ROIs, florzolotau (18F) SUVRs and

brain volumes were calculated for each PSP case.

Path analysis was performed using ROI values and PSP Rating Scale subscores

in each clinical domain to examine the dependencies of key symptoms on tau

depositions and volume declines, as well as the dependencies of volume declines on tau

depositions in characteristic brain regions under possible causal assumptions (Figure S5).

Path analysis across all cases (Fig. S5) indicated that atrophy exerted a predominant direct effect on clinical symptoms, likely reflecting the stronger structure-symptom associations observed in advanced disease stages. Therefore, we analyzed the patients divided into early, intermediate, and advanced groups based on the disease duration to assess transitions of the associations along the time course (Figs. 3 and S6). In the path analysis of the ocular motor domain, a causality direction from tau pathologies to atrophy was the most pronounced at early and intermediate phases, in contrast to the predominance of the direction from atrophy to symptoms at the advanced stage. In the analysis of the gait and midline domain, the dependency of volume declines on tau accumulations was prominent at the early stage, similar to the ocular motor domain, whereas the causal connection between atrophy to symptoms already became predominant at the intermediate stage. In the analysis of the limb motor domain, the direct dependency direction from tau depositions to symptoms dominated at the early stage, which was replaced by the pathway from tau depositions to remote atrophy and then the pathway from atrophy to symptoms along the disease time course.

Discussion

In this study, we generated high-contrast maps delineating tau pathology and regional volume loss in the brains of PSP cases, representing the largest cohort analyzed to date. Our analyses revealed, for the first time, the spatial distribution of tau deposits and brain atrophy in relation to core symptomatic domains captured by the PSP Rating Scale. Integrating these findings with path analyses of clinical and neuroimaging data,

we demonstrate that subcortical tau accumulation leads to neuronal loss and localized

tissue atrophy, directly contributing to symptom expression. In contrast, neocortical tau

deposits appear to induce network dysfunction as well, resulting in secondary neuronal

degeneration in anatomically distant regions. These distinct mechanisms of tau-induced

neurotoxicity underpin the differential patterns of subcortical and neocortical pathology

in PSP.

Comparisons between the PSP and control groups revealed a spatial concordance

of tau pathology and volume reduction in the midbrain, basal ganglia, subthalamic

nucleus, and adjacent thalamic regions of PSP brains (Fig. 1). In contrast, despite the

presence of tau aggregates in the primary and supplementary motor cortices, significant

neocortical atrophy ($p < 0.05$, FWEp) was not observed (Fig. 1). These findings suggest

that morphometric alterations in PSP are predominantly subcortical, while neocortical

neuronal loss may be more heterogeneous across individuals. Indeed, reduced volumes

in posterior cortical areas were evident in patients exhibiting severe "gait and midline"

and "limb motor" symptoms (Fig. 2C, D).

Although prior neuropathological studies have reported interneuron loss in the

primary motor cortex alongside extensive glial and neuronal tau inclusions,[31] the

relative preservation of large pyramidal neurons may mitigate detectable atrophy in this

region. This notion aligns with a previous report documenting sparing of the motor

cortex volume in PSP-Richardson (RS) type.[15] Conversely, degeneration of cortico-

cortical projection neurons was identified in the pre-supplementary motor area,[31] and

tau-induced axonal pathology may also disrupt intercortical pathways originating from

the primary motor cortex. These degenerative processes could impair the delivery of

trophic support from axonal terminals to downstream regions, such as the angular gyrus,

ultimately leading to transneuronal degeneration and atrophy in areas remote from

dense tau accumulations.

We observed substantial spatial overlap between regions of tau accumulation and

brain atrophy, which were closely associated with total PSP Rating Scale scores and

subscores in the "ocular motor" and "gait and midline" domains. These voxel-wise

correlational analyses primarily identified subcortical structures. Notably, impairments

in the "ocular motor" domain showed strong correlations with both tau pathology and

volume loss in the midbrain. Upgaze palsy is a well-established ocular motor sign of

PSP, and prior lesion studies have implicated the rostral interstitial nucleus of the medial

longitudinal fasciculus (riMLF) in the midbrain as a critical site underlying this

dysfunction.[32] The present tau and atrophy maps revealed the involvement of medial

midbrain regions encompassing the medial longitudinal fasciculus (highlighted in

yellow in Fig. 2B and the upper left panel of Fig. 3), supporting the presence of local

neurodegeneration driven by tau pathology in key structures responsible for generating

fast vertical eye movements.

Importantly, the superior colliculus (SC) plays a modulatory role in the activity of

riMLF, which is critical for controlling eye movements.[33] Disruptions in the sequential

pathways linking the globus pallidus to the SC—via the subthalamic nucleus and

substantia nigra pars reticulata (SNr)—have been implicated in the pathophysiology of

ocular motor dysfunction.[34,35] Consistently, our analysis identified the globus pallidus,

subthalamic nucleus, and SNr as regions showing significant associations between tau

deposition, structural atrophy, and impairment in the "ocular motor" domain

(highlighted in yellow in Fig. 2B). Furthermore, path analysis (upper panel in Fig. 3)

suggests a sequential relationship among tau accumulation, atrophy, and symptom

progression, unfolding over several years. This timeline aligns with clinical

observations that gaze abnormalities typically become prominent during the middle to

late stages of PSP, particularly in non-classical phenotypes.[36]

As mentioned above, regions exhibiting tau deposition and volume loss

associated with the "gait and midline" domain substantially overlapped with subcortical

areas implicated in "ocular motor" deficits, whereas the brainstem appeared to be less

involved. The subcortical locomotive network includes the striatum, globus pallidus,

subthalamic nucleus, mesencephalic locomotor region, and pontine and medullary

reticular formations.[37,38] Among these, the subthalamic nucleus and basal ganglia

(highlighted yellow in Fig. 2B and the middle-left panel of Fig. 3) were prominently

identified in our correlational analysis. These structures are implicated from the early

stages of PSP, including phenotypes with spatially restricted tau accumulation such as

PSP-parkinsonism and PSP-pure akinesia with gait freezing,[39] and are accordingly more

consistently involved in locomotive impairment than the brainstem.

Gait disturbances, particularly balance difficulties and falls, frequently represent

the earliest clinical manifestations of PSP, reinforcing the association between these

subcortical structures and the "gait and midline" subscores. Correspondingly, path

analysis (middle panels of Fig. 3) suggested a causal pathway from early-stage tau

accumulation to impairments in this functional domain within one year of symptom

onset.

In addition, tau deposition and atrophy in distinct neocortical regions were also

correlated with "gait and midline" symptoms, indicating that tau-associated neuronal

loss in remote areas may contribute to these deficits. Tau accumulation in the lateral

occipital cortex, including the secondary visual cortex (V_2), may disrupt visual

processing relevant to locomotion,[40] while atrophy in the precuneus may compromise

sensory integration required for spatiotemporal control of motor behavior.[40,41] Given the

known functional connectivity between V_2 and the dorsal precuneus,[42] tau deposition in

V_2 may adversely affect neuronal viability in the precuneus via axonal projections.

Alternatively, tau pathology in the thalamus may impact the precuneus through its

strong structural and functional connectivity.[43]

7   Unlike the "ocular motor" and "gait and midline" domains, subscores of the "limb

motor" domain primarily correlated with pathological changes in the neocortex. Tau

deposition and atrophy in distinct cortical regions were associated with this domain (Fig.

2D).

We also found that volume loss in the angular and supramarginal gyri, along with

the temporal lobes was closely associated with limb motor deficits, consistent with the

well-established contribution of this parietal region in limb apraxia.[44, 2] Prior studies

have shown activation of the fronto–temporo–parietal network via the superior

longitudinal fasciculus during pantomime and imitation tasks, supporting its role in

apraxia and its association with temporal and parietal atrophy.[45] The present results

further indicate that tau accumulation in the primary motor and primary somatosensory

cortices may exert secondary effects on neuronal integrity in downstream projection

sites. In support of this interpretation, the superior longitudinal fasciculus, which

connects the primary motor cortex and angular gyrus,[46] may serve as a conduit for

transneuronal degeneration, eventually contributing to volume loss in this region.

Moreover, the motor cortex and parietal lobe, including the angular gyrus, are

conceived to form a sensory-motor integration loop, and dysfunction within this loop

may contribute to dystonia, a key feature of the "limb motor" domain.[47]

Although the domain also includes Parkinsonian features such as limb rigidity

and tremor, subcortical regions typically associated with the extrapyramidal system

were not prominently implicated in the present analysis. This may reflect the item

composition of the domain, which emphasizes functions, such as dystonia and fine

motor tasks (e.g., finger and toe tapping), that are more reliant on cortical motor

circuits.[47][48]

Tau deposition in the supplementary and primary motor cortices was associated

with the mentation domain of the PSP Rating Scale, whereas involvement of the

supplementary and pre-supplementary motor cortices and the inferior frontal cortex

(IFC) correlated with FAB scores (Fig. S7), indicating that tau accumulation in these

regions contributes to frontal lobe functions.[49] Notably, FAB scores were not correlated

with atrophy. In contrast, our recent work restricted analysis to patients with

Richardson's syndrome and identified a 'latent' network containing the dorsomedial

frontal cortex (dmFC), premotor cortex (PMC), and IFC associated with FAB scores in

the absence of local tau accumulations.[50] In the current study, however, FAB scores

were associated with tau deposition in cortical areas corresponding to the dmFC, PMC,

and IFC. The discrepancy between studies may reflect differing cohort compositions;

our cohort included both Richardson's syndrome (n = 43) and non-RS patients (n = 15).

Collectively, these findings suggest that the association between tau pathology and

executive dysfunction, particularly within the frontal lobe, varies depending on the PSP

subtypes included in the analysis.

Our path analysis (lower panel of Fig. 3) suggested a directional relationship from

early-stage tau deposition to limb motor impairments by less than one year of onset,

indicating that tau-induced dysfunction within cortical motor areas may precede

significant neuronal loss. As the disease progresses, atrophy in distant projection sites

likely emerges, contributing to the focal and network-level motor deficits observed in

advanced PSP.

Despite the current findings highlighting localized tau pathologies and neuronal

loss associated with specific symptom domains in PSP, the large-scale impact of tau

deposition on neural network degeneration, particularly remote atrophy and functional

impairments, remains to be elucidated. Future investigations employing tract-specific

analyses, such as diffusion tensor imaging, will be essential to address this gap. In this

study, we did not account for PSP subtypes when examining pathology-symptom

relationships, as the domain-based structure of the PSP Rating Scale is independent of

clinical phenotype classifications. Consequently, the distinct tau topographies associated

with PSP-RS versus other variants, such as PSP-parkinsonism, and their links to

symptomatic heterogeneity, are yet to be clarified. Furthermore, while our path analysis

suggested temporal sequences linking tau accumulation and regional atrophy to specific

symptom domains, these observations require validation in longitudinal neuroimaging

studies.

In conclusion, by leveraging high-contrast PET imaging of four-repeat tau

assemblies, the present study delineates the spatiotemporal profiles of

neurodegenerative tau pathologies underlying the emergence and progression of specific

symptom domains in PSP. This approach holds promise for predicting clinical outcomes

across the natural course of the disease and in the context of anti-tau therapeutic

interventions.

Acknowledgment

This study was supported by AMED under grants JP19dm0207072,

JP24wm0625001, JP24zf0127012; MEXT KAKENHI grant JP21K15705; JST CREST

grants JPMJMS2024; Biogen Inc.; and APRINOIA Therapeutics. We thank all patients

and their caregivers, as well as volunteers, for their participation in this study; clinical

research coordinators; PET and MRI operators; radiochemists; and research ethics

advisers at Quantum Science and Technology (QST) for their assistance with the current

projects. We acknowledge the support of M. Kubota, Y. Yamamoto, and S. Kitamura at

QST. We thank APRINOIA Therapeutics for kindly sharing the precursor of florzolotau

(18F). We acknowledge the support of S. Hirano at the Department of Neurology, Chiba

University on patient recruitment; T. Hatano, T. Tsunemi, N. Nishikawa, K. Nishioka

(currently working at The Juntendo Tokyo Koto Geriatric Medical Center), Y.

Yamashita, Y. Motoi, and S. Saiki (currently working at the University of Tsukuba) at

the Department of Neurology, Juntendo University School of Medicine; I. Aiba at the

Department of Neurology, National Hospital Organization Higashinagoya National

Hospital; Y. Nakano (currently working at The Feinstein Institute for Medical Research)

at the Department of Neurology, Chibaken Saiseikai Narashino Hospital; T. Yuasa at the

Department of Neurology, Kamagaya General Hospital; H. Imai at the Tokyo Rinkai

Hospital; Y. Nishida and Y. Yagi at the Department of Neurology, Tokyo Medical and

Dental University; S. Furukawa at the Narita Red Cross Hospital; M. Seki at the

Department of Neurology, Keio University School of Medicine; and T. Takeda and I.

Isose at the Department of Neurology, Chiba-East Hospital.

Potential Conflicts of Interest

H. Shimada, M.-R.Z., and M.H. hold patents on compounds related to this

report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672/ZL201710407246.4).

Data Access.

The Principal Author had full access to all the data used in this study and takes

full responsibility for the integrity of the data, the accuracy of the analyses, and the

decision to publish the results.

Author Contributions

Y.K., M.H., and H.E. contributed to drafting and revision of the manuscript for

content, including medical writing; Y.K., R.G., Y.C., K.O., H.M., M.I., S.M., Y.M., T.K.,

K.M., K.H., S.K., M.O., K. Takahata, and N.K. contributed to the acquisition of data;

Y.K., M.H., H.E., H. Shinotoh, H. Shimada, and K. Tagai contributed to the study

concept and design; Y.K., A.O., C.S., K.K., M.-R.Z., T.T., M.H., and H.E. contributed to

the analysis and interpretation of data.

References

1.   Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of

variants of progressive supranuclear palsy. *Curr Opin Neurol*. Aug 2010;23(4):394-400.

doi:10.1097/WCO.0b013e32833be924

2.   McGeoch PD, Brang D, Ramachandran VS. Apraxia, metaphor and mirror

neurons. *Med Hypotheses*. 2007;69(6):1165-8. doi:10.1016/j.mehy.2007.05.017

3.   Steele JC, Richardson JC, Olszewski J. Progressive Supranuclear Palsy. A

Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum

with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia. *Arch

Neurol*. Apr 1964;10:333-59. doi:10.1001/archneur.1964.00460160003001

4.   Williams DR, Holton JL, Strand C, et al. Pathological tau burden and

distribution distinguishes progressive supranuclear palsy-parkinsonism from

Richardson's syndrome. *Brain*. Jun 2007;130(Pt 6):1566-76. doi:10.1093/brain/awm104

5.   Cairns NJ, Ghoshal N. FUS: A new actor on the frontotemporal lobar

degeneration stage. *Neurology*. Feb 2 2010;74(5):354-6.

doi:10.1212/WNL.0b013e3181ce5dd6

6.　　　Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive

supranuclear palsy. *J Neurol Sci*. Jun 15 2003;210(1-2):57-60. doi:10.1016/s0022-

510x(03)00014-5

7.　　　Dutt S, Binney RJ, Heuer HW, et al. Progression of brain atrophy in PSP and

CBS over 6 months and 1 year. *Neurology*. Nov 8 2016;87(19):2016-2025.

doi:10.1212/WNL.0000000000003305

8.　　　Kimura T, Ono M, Seki C, et al. A quantitative in vivo imaging platform for

tracking pathological tau depositions and resultant neuronal death in a mouse model.

Eur J Nucl Med Mol Imaging. Nov 2022;49(13):4298-4311. doi:10.1007/s00259-022-

05898-3

9.　　　Priyanka, Qamar SH, Visanji NP. Toward an animal model of Progressive

Supranuclear Palsy. *Front Neurosci*. 2024;18:1433465. doi:10.3389/fnins.2024.1433465

10.　　　Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in

progressive supranuclear palsy. *Acta Neuropathol*. Aug 2020;140(2):99-119.

doi:10.1007/s00401-020-02158-2

11.　　　Tagai K, Ono M, Kubota M, et al. High-Contrast In Vivo Imaging of Tau

Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. *Neuron*. Jan 6

2021;109(1):42-58 e8. doi:10.1016/j.neuron.2020.09.042

12.　　　Endo H, Tagai K, Ono M, et al. A Machine Learning-Based Approach to

Discrimination of Tauopathies Using [^{18}F]PM-PBB3 PET Images. *Mov Disord*. Nov

2022;37(11):2236-2246. doi:10.1002/mds.29173

13.　　　Li L, Liu FT, Li M, et al. Clinical Utility of (18) F-APN-1607 Tau PET

Imaging in Patients with Progressive Supranuclear Palsy. *Mov Disord*. Oct

2021;36(10):2314-2323. doi:10.1002/mds.28672

14.   Hong J, Lu J, Liu F, et al. Uncovering distinct progression patterns of tau

deposition in progressive supranuclear palsy using [(18)F]Florzolotau PET imaging and

subtype/stage inference algorithm. *EBioMedicine*. Nov 2023;97:104835.

doi:10.1016/j.ebiom.2023.104835

15.   Whitwell JL, Tosakulwong N, Botha H, et al. Brain volume and flortaucipir

analysis of progressive supranuclear palsy clinical variants. *Neuroimage Clin*.

2020;25:102152. doi:10.1016/j.nicl.2019.102152

16.   Marquie M, Normandin MD, Meltzer AC, et al. Pathological correlations of [F-

18]-AV-1451 imaging in non-alzheimer tauopathies. *Ann Neurol*. Jan 2017;81(1):117-

128. doi:10.1002/ana.24844

17.   Malpetti M, Kaalund SS, Tsvetanov KA, et al. In Vivo (18)F-Flortaucipir PET

Does Not Accurately Support the Staging of Progressive Supranuclear Palsy. *J Nucl

Med*. Jul 2022;63(7):1052-1057. doi:10.2967/jnumed.121.262985

18.   Bauer T, Brendel M, Zaganjori M, et al. Pragmatic algorithm for visual

assessment of 4-Repeat tauopathies in [(18)F]PI-2620 PET Scans. *Neuroimage*. Feb 1

2025;306:121001. doi:10.1016/j.neuroimage.2025.121001

19.   Mena AM, Chen R, Graff-Guerrero A, Martin SL, Uribe C, Strafella AP. Tau in

Atypical Parkinsonisms: A Meta-Analysis of in Vivo PET Imaging Findings. *Mov

Disord Clin Pract*. Dec 2023;10(12):1725-1737. doi:10.1002/mdc3.13885

20.   Frontzkowski L, Gnorich J, Gross M, et al. Developing a novel reference

region for [(18)F]PI-2620-PET imaging to facilitate the assessment of 4-repeat

tauopathies. *Eur J Nucl Med Mol Imaging*. Jun 10 2025;doi:10.1007/s00259-025-

07396-8

21.   Tezuka T, Takahata K, Seki M, et al. Evaluation of [(18)F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. *Brain Commun*. 2021;3(4):fcab190. doi:10.1093/braincomms/fcab190

22.   Araki N, Takeda T, Takado Y, et al. Florzolotau (18F) PET provides in-vivo measures of tau pathology in progressive supranuclear palsy: An imaging-postmortem correlation study. *medRxiv*. 2025:2025.12.02.25340863. doi:10.64898/2025.12.02.25340863

23.   Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord*. Jun 2017;32(6):853-864. doi:10.1002/mds.26987

24.   Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. *Brain*. Jun 2007;130(Pt 6):1552-65. doi:10.1093/brain/awm032

25.   Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. *Neurology*. Dec 12 2000;55(11):1621-6. doi:10.1212/wnl.55.11.1621

26.   Yamane T, Ishii K, Sakata M, et al. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of (11)C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study. *Eur J Nucl Med Mol Imaging*. May 2017;44(5):850-857. doi:10.1007/s00259-016-3591-2

27.   Maeda J, Ji B, Irie T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. *J Neurosci*. Oct 10 2007;27(41):10957-68. doi:10.1523/JNEUROSCI.0673-07.2007

28. Tagai K, Ikoma Y, Endo H, et al. An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with (18)F-PM-PBB3 ((18)F-APN-1607). *Neuroimage*. Dec 1 2022;264:119763. doi:10.1016/j.neuroimage.2022.119763

29. Rosseel Y. lavaan: An R Package for Structural Equation Modeling. *J Stat Softw*. May 2012;48(2):1-36. doi:DOI 10.18637/jss.v048.i02

30. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant*. Mar 2013;48(3):452-8. doi:10.1038/bmt.2012.244

31. Halliday GM, Macdonald V, Henderson JM. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. *Brain*. Oct 2005;128(Pt 10):2272-80. doi:10.1093/brain/awh596

32. Buttner-Ennever JA, Buttner U, Cohen B, Baumgartner G. Vertical glaze paralysis and the rostral interstitial nucleus of the medial longitudinal fasciculus. *Brain*. Mar 1982;105(Pt 1):125-49. doi:10.1093/brain/105.1.125

33. Dash S, Nazari SA, Yan X, Wang H, Crawford JD. Superior Colliculus Responses to Attended, Unattended, and Remembered Saccade Targets during Smooth Pursuit Eye Movements. *Front Syst Neurosci*. 2016;10:34. doi:10.3389/fnsys.2016.00034

34. Lal V, Truong D. Eye movement abnormalities in movement disorders. *Clin Park Relat Disord*. 2019;1:54-63. doi:10.1016/j.prdoa.2019.08.004

35. Halliday GM, Hardman CD, Cordato NJ, Hely MA, Morris JG. A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. *Brain*. Apr 2000;123 (Pt 4):724-32. doi:10.1093/brain/123.4.724

36.   Phokaewvarangkul O, Bhidayasiri R. How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. *Transl Neurodegener*. 2019;8:20. doi:10.1186/s40035-019-0160-1

37.   la Fougere C, Zwergal A, Rominger A, et al. Real versus imagined locomotion: a [18F]-FDG PET-fMRI comparison. *Neuroimage*. May 1 2010;50(4):1589-98. doi:10.1016/j.neuroimage.2009.12.060

38.   Hinton DC, Thiel A, Soucy JP, Bouyer L, Paquette C. Adjusting gait step-by-step: Brain activation during split-belt treadmill walking. *Neuroimage*. Nov 15 2019;202:116095. doi:10.1016/j.neuroimage.2019.116095

39.   Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. *Lancet Neurol*. Mar 2009;8(3):270-9. doi:10.1016/S1474-4422(09)70042-0

40.   Bommarito G, Putzolu M, Avanzino L, et al. Functional Correlates of Action Observation of Gait in Patients with Parkinson's Disease. *Neural Plast*. 2020;2020:8869201. doi:10.1155/2020/8869201

41.   Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioural correlates. *Brain*. Mar 2006;129(Pt 3):564-83. doi:10.1093/brain/awl004

42.   Zhang S, Li CS. Functional connectivity mapping of the human precuneus by resting state fMRI. *Neuroimage*. Feb 15 2012;59(4):3548-62. doi:10.1016/j.neuroimage.2011.11.023

43.   Cunningham SI, Tomasi D, Volkow ND. Structural and functional connectivity of the precuneus and thalamus to the default mode network. *Hum Brain Mapp*. Feb 2017;38(2):938-956. doi:10.1002/hbm.23429

44. Metaireau M, Osiurak F, Seye A, Lesourd M. The neural correlates of limb apraxia: An anatomical likelihood estimation meta-analysis of lesion-symptom mapping studies in brain-damaged patients. *Neurosci Biobehav Rev*. Jul 2024;162:105720. doi:10.1016/j.neubiorev.2024.105720

45. Vry MS, Tritschler LC, Hamzei F, et al. The ventral fiber pathway for pantomime of object use. *Neuroimage*. Feb 1 2015;106:252-63. doi:10.1016/j.neuroimage.2014.11.002

46. Wang X, Pathak S, Stefaneanu L, Yeh FC, Li S, Fernandez-Miranda JC. Subcomponents and connectivity of the superior longitudinal fasciculus in the human brain. *Brain Struct Funct*. May 2016;221(4):2075-92. doi:10.1007/s00429-015-1028-5

47. Perruchoud D, Murray MM, Lefebvre J, Ionta S. Focal dystonia and the Sensory-Motor Integrative Loop for Enacting (SMILE). *Front Hum Neurosci*. 2014;8:458. doi:10.3389/fnhum.2014.00458

48. Witt ST, Laird AR, Meyerand ME. Functional neuroimaging correlates of finger-tapping task variations: an ALE meta-analysis. *Neuroimage*. Aug 1 2008;42(1):343-56. doi:10.1016/j.neuroimage.2008.04.025

49. Nachev P, Kennard C, Husain M. Functional role of the supplementary and pre-supplementary motor areas. *Nat Rev Neurosci*. Nov 2008;9(11):856-69. doi:10.1038/nrn2478

50. Hori Y, Endo H, Tagai K, et al. Remote Cortical Network for Frontal Cognitive Symptoms Derived from Tau Accumulation in Progressive Supranuclear Palsy. *bioRxiv*. 2025-01-01 00:00:00 2025;

Figure Legends

Figure 1: Topologies of tau accumulation and atrophy in the brains of PSP patients relative to controls

Voxel-based analysis showed an elevated tau PET tracer retention (red) primarily in the basal ganglia and frontal lobes, atrophy (green) in the basal ganglia, thalamus, and cerebellar hemispheres, and their spatial overlaps (yellow) in the midbrain and basal ganglia of the PSP group relative to HCs ($P < 0.05$, FWEp). Cluster size thresholds (k) are 115 voxels for tau accumulation and 91 voxels for atrophy. Areas are highlighted in the standard anatomical space of the brain.

PSP, progressive supranuclear palsy; HC, healthy control; FWEp, family-wise error correction at peak-level.

Figure 2: Distributions of tau accumulation (red), atrophy (green), and their overlaps (yellow) correlating with neurological symptoms.

(A) Total PSP Rating Scale scores correlated with both tau accumulation and atrophy in the subthalamic nucleus and globus pallidus. Association with tau accumulation was also found in neocortical regions, including the primary and supplementary motor cortices. Cluster size thresholds (k) are 4229 voxels for tau accumulation and 7338 voxels for atrophy. (B) "Ocular motor" subscores correlated with tau accumulation and atrophy commonly in the midbrain tegmentum and globus pallidus. Cluster size thresholds (k) are 3658 voxels for tau accumulation and 7031 voxels for atrophy. (C) "Gait and midline" subscores correlated with tau accumulation in the globus pallidus to thalamic area and occipital cortex and atrophy in the globus pallidus to the thalamic area, occipital cortex, and precuneus. Cluster size thresholds (k) are 2480 voxels for tau accumulation and 2326 voxels for atrophy. (D) "Limb motor" subscores correlated with

tau accumulation in the primary motor and somatosensory cortices and atrophy in the

angular and supramarginal gyri and temporal gray and white matter. Cluster size

thresholds (k) are 43882 voxels for tau accumulation and 2489 voxels for atrophy. Areas

are highlighted in the standard anatomical space of the brain.

All statistical thresholds were set at $P < 0.05$, FWEc.

PSP, progressive supranuclear palsy; FWEc, family-wise error correction at the cluster-

level.

Figure 3: Path analysis revealed temporal transitions in the causal relationships

among tau deposition, brain atrophy, and clinical symptoms across disease

progression

Causality directions were examined in the groups classified by the disease duration

(early, 1 year; intermediate, 2 years; advanced, ≥3 years). In the "ocular motor" domain,

tau pathology primarily drove atrophy in the early and intermediate stages, while

atrophy more strongly predicted symptoms at the advanced stage. In the "gait and

midline" domain, tau-driven atrophy was evident early, but atrophy-to-symptom

causality became dominant by the intermediate stage. In the "limb motor" domain, early

symptoms were directly linked to tau deposition, with later stages showing a sequential

pathway from tau to atrophy and then to symptoms.

Table 1: Demographic characteristics.

	HC (n = 53)	PSP (n = 58)	P-value
Women, n (%)	24 (45.3)	25 (43.1)	0.85
Age, mean ± SD (years)	60.8 ± 13.3	71.6 ± 7.7	< 0.001
Disease duration, mean ± SD (years)	N/A	3.9 ± 3.2	N/A

PSP Rating Scale total (point), mean ± SD/(maximum)	0.6 ± 1.3/100	36.2 ± 16.5/100	< 0.001
History (point), mean ± SD/(maximum)	0.0 ± 0.1/24	8.7 ± 4.7/24	< 0.001
Mentation (point), mean ± SD/(maximum)	0.0 ± 0.0/16	2.7 ± 3.1/16	< 0.001
Bulbar (point), mean ± SD/(maximum)	0.0 ± 0.0/8	2.8 ± 1.9/8	< 0.001
Ocular motor (point), mean ± SD/(maximum)	0.1 ± 0.5/16	7.2 ± 3.8/16	< 0.001
Limb motor (point), mean ± SD/(maximum)	0.4 ± 0.9/16	4.3 ± 2.3/16	< 0.001
Gait and midline (point), mean ± SD/(maximum)	0.0 ± 0.2/20	10.5 ± 5.0/20	< 0.001
FAB/(maximum)	16.6 ± 1.1/18	12.0 ± 4.1/18	<0.001

Data are expressed as the number (%), mean ± SD for normally distributed variables.

HC, healthy control; PSP, progressive supranuclear palsy; FAB, Frontal Assessment Battery

Table 2: Demographic characteristics in three disease duration subgroups.

	Disease duration			P-value
	1 year (n = 10)	2 years (n = 13)	≥ 3 years (n = 35)	
Women, n (%)	2 (20.0)	6 (46.2)	17 (48.6)	0.265
Age, mean±SD (years)	68.2 ± 8.6	74.1 ± 8.4	71.7 ±7.0	0.192
Disease duration, mean ± SD (years)	1.0 ± 0.0	2.0 ± 0.0####	5.4 ± 3.4****	<0.001
PSP Rating Scale total(point), mean ±SD/(maximum)	27.2 ±10.9/100	26.5 ± 11.6##/100	42.4 ± 16.7*/100	0.002
History (point), mean ± SD/(maximum)	6.4 ± 4.0/24	5.6 ± 3.4##/24	10.4 ± 4.6/24	0.005
Mentation (point), mean ± SD/(maximum)	1.8 ± 1.8/16	1.9 ± 2.1/16	3.3 ± 3.6/16	0.465
Bulbar (point), mean ± SD/(maximum)	2.0 ± 1.5/8	1.3 ± 0.8###/8	3.6 ± 1.9/8	<0.001
Ocular motor (point), mean ± SD/(maximum)	6.6 ± 3.1/16	5.6 ± 3.0/16	7.9 ± 4.1/16	0.15
Limb motor (point), mean ± SD/(maximum)	3.3 ± 1.6/16	4.1 ± 1.7/16	4.7 ± 2.6/16	0.324
Gait and midline (point), mean ± SD/(maximum)	7.1 ± 4.2/20	8.0 ± 5.2#/20	12.4 ± 4.2**/20	0.002
FAB (point), mean ± SD/(maximum)	12.3 ±4.3/18	12.8 ± 3.0/18	11.6 ± 4.2/18	0.64

Data are expressed as the number (%), mean ± SD for normally distributed variables.
****P < 0.0001, **P < 0.01, *P < 0.05 versus 1 year group post hoc Dunn's test
####P < 0.0001, ##P < 0.01, #P < 0.05 versus 3 years or later group post hoc Dunn's test

Figure 1

atrophy ▮ p<0.05, FWEp, tau ▮ p<0.05, FWEp, overlap ▮

Figure 2

(A) Total PSP Rating Scale score

(B) Ocular motor

(C) Gait and midline

(D) Limb motor

atrophy ▮ p<0.05, FWEc, tau ▮ p<0.05, FWEc, overlap ▮

Figure 3

Disease duration	1 year n=10	2 years n=13	≥3 years n=35
Ocular motor	Tau→atrophy** 0.744 / Tau→ocular motor 0.309 / Atrophy→ocular motor 0.514	Tau→atrophy* 0.509 / Tau→ocular motor*** 0.618 / Atrophy→ocular motor 0.134	Tau→atrophy 0.193 / Tau→ocular motor** 0.320 / Atrophy→ocular motor*** 0.447
Gait and midline	Tau→atrophy*** 0.809 / Tau→gait and midline 0.594 / Atrophy→gait and midline 0.178	Tau→atrophy* 0.458 / Tau→gait and midline 0.093 / Atrophy→gait and midline*** 0.643	Tau→atrophy 0.115 / Tau→gait and midline*** 0.347 / Atrophy→gait and midline*** 0.513
Limb motor	Tau→atrophy 0.038 / Tau→limb motor*** 0.753 / Atrophy→limb motor* 0.349	Tau→atrophy** 0.594 / Tau→limb motor 0.046 / Atrophy→limb motor 0.274	Tau→atrophy*** 0.477 / Tau→limb motor*** 0.610 / Atrophy→limb motor** 0.282

Significant at p<0.05*, p<0.01**, p<0.001***